1,166 reports of this reaction
1.1% of all METFORMIN HCL reports
#20 most reported adverse reaction
HYPOGLYCAEMIA is the #20 most commonly reported adverse reaction for METFORMIN HCL, manufactured by Ascend Laboratories, LLC. There are 1,166 FDA adverse event reports linking METFORMIN HCL to HYPOGLYCAEMIA. This represents approximately 1.1% of all 105,459 adverse event reports for this drug.
Patients taking METFORMIN HCL who experience hypoglycaemia should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HYPOGLYCAEMIA is a less commonly reported adverse event for METFORMIN HCL, but still significant enough to appear in the safety profile.
In addition to hypoglycaemia, the following adverse reactions have been reported for METFORMIN HCL:
The following drugs have also been linked to hypoglycaemia in FDA adverse event reports:
HYPOGLYCAEMIA has been reported as an adverse event in 1,166 FDA reports for METFORMIN HCL. This does not prove causation, but indicates an association observed in post-market surveillance data.
HYPOGLYCAEMIA accounts for approximately 1.1% of all adverse event reports for METFORMIN HCL, making it a notable side effect.
If you experience hypoglycaemia while taking METFORMIN HCL, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.